Premium
7‐Methoxy‐luteolin‐8‐C‐ β ‐6‐deoxy‐xylo‐pyranos‐3‐uloside exactly (mLU8C‐PU) isolated from Arthraxon hispidus inhibits migratory and invasive responses mediated via downregulation of MMP‐9 and IL‐8 expression in MCF‐7 breast cancer cells
Author(s) -
Kim SooJin,
Pham ThuHuyen,
Bak Yesol,
Ryu HyungWon,
Oh SeiRyang,
Yoon DoYoung
Publication year - 2018
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.22620
Subject(s) - luteolin , protein kinase c , downregulation and upregulation , nf κb , signal transduction , microbiology and biotechnology , activator (genetics) , 12 o tetradecanoylphorbol 13 acetate , kinase , chemistry , phosphorylation , biology , cancer research , biochemistry , receptor , flavonoid , gene , phorbol ester , antioxidant
7‐Methoxy‐luteolin‐8‐C‐ β ‐6‐deoxy‐xylo‐pyranos‐3‐uloside (mLU8C‐PU) is a glycosylflavone of luteolin isolated from Arthraxon hispidus (Thunb.). Luteolin is known to exert anti‐migratory and anti‐invasive effects on tumor cells. However, there are no reports on the effects of mLU8C‐PU on tumor invasiveness and associated signaling pathways. In this study, we demonstrated the anti‐migratory and anti‐invasive effects of mLU8C‐PU in 12‐ O ‐tetradecanoylphorbol‐13‐acetate (TPA)‐treated MCF‐7 breast cancer cells. We also investigated the effect of mLU8C‐PU on invasion‐ related signal transducers, including protein kinase Cα (PKCα), c‐Jun N terminal kinase (JNK), activator protein‐1 (AP‐1), and nuclear factor‐kappa B (NF‐ĸB). TPA‐induced membrane translocation of PKCα, phosphorylation of JNK, and the nuclear translocations of AP‐1 and NF‐κB were downregulated by mLU8C‐PU in MCF‐7 cells. In addition, mLU8C‐PU also inhibited matrix metalloproteinase‐9 (MMP‐9) and interleukin‐8 (IL‐8) expression. These results indicate that mLU8C‐PU inhibits migratory and invasive responses in MCF‐7 breast cancer cells by suppressing MMP‐9 and IL‐8 expression through mitigating TPA‐induced PKCα, JNK activation, and the nuclear translocation of AP‐1 and NF‐κB. These results suggest that mLU8C‐PU may be used as an anti‐metastatic agent.